Humvira Therapeutics (赫睿源)

Humvira Therapeutics (赫睿源) is building next-generation in vivo gene therapy platforms for severe inherited diseases. For investor and media inquiries, please contact our team below.

Company Snapshot

Humvira Therapeutics is a genetic medicine company focused on developing in vivo gene therapy platforms targeting severe rare diseases, including central nervous system lysosomal storage disorders, primary immunodeficiencies, and hemophilia A.

The company’s pipeline is built on complementary in vivo lentiviral and AAV gene delivery technologies designed to enable durable, single-administration therapeutic effects across multiple organ systems.

Pipeline Focus

• Central Nervous System Lysosomal Storage Disorders (CNS-LSD)

• Severe Combined Immunodeficiency (SCID) and Primary Immunodeficiencies

• Hemophilia A — Plenacogene parvovec (AAV5 / AAV8)

For Investors & Media

Humvira Therapeutics (赫睿源)

Investor.Relations@humvira.com

Humvira Therapeutics operates in China through Kareke Biotechnology Co., Ltd. (康瑞克生物科技有限公司).

This website may contain forward-looking statements regarding development programs and future plans. Actual results may differ materially due to risks and uncertainties inherent in biotechnology research and development.